A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.

Trial Profile

A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
  • Indications Metabolic disorders
  • Focus Therapeutic Use
  • Acronyms SIRONA
  • Sponsors Longeveron
  • Most Recent Events

    • 09 Jan 2018 According to a National Institutes of Health media release, Dr. Anthony Oliva, Ph.D, will be the principle investigator of the study.
    • 29 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top